Plasma Circular RNA DYM Related to Major Depressive Disorder and Rapid Antidepressant Effect Treated by Visual Cortical Repetitive Transcranial Magnetic Stimulation

Song, Ruize; Bai, Ying; Li, Xianrui; Zhu, Jianli; Zhang, Hongxing; Shi, Yachen; Li, Kun; Bi, Wang; Zhang, Haisan; Yang, Yongfeng; Zhang, Zhijun

doi:10.1016/j.jad.2020.05.109

Cited by 28 publications

(19 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, in vivo and in vitro research further demonstrated that circ-DYM expression can alter microglial activation by affecting miR-9 activity (targeting HECTD1 gene) [69]. In addition, in an independent cohort, including 60 depressed patients and 32 healthy subjects, significantly reduced expression of plasma circDYM was found in depressed patients [72]. Furthermore, a recent study revealed that the expression of circSTAG1 was significantly lower both in peripheral blood of depressed patients and in hippocampus tissues and peripheral blood of CUMS mouse [70].…”

Section: Circrnas As Diagnostic Biomarkers For Depressionsupporting

confidence: 52%

“…Therefore, circRNAs may play an important pathophysiological role in some psychiatric disorders (e.g., depression [68][69][70][71][72][73], schizophrenia [74][75][76][77]) via certain underlying functions, including neurogenesis, neuro-inflammation, and autophagy [65]. Additionally, circRNAs may be used as valuable biomarkers for diagnosis and therapy due to their high stability and resistance to RNase R digestion, high evolutionary conservation, abundance in various eukaryotic cells, and cell-/tissue-specificity [78][79][80].…”

Section: Circrna Biogenesis and Functionmentioning

confidence: 99%

“…To determine whether circRNAs can direct the clinical treatment of depression, direct evidence was provided firstly by Cui et al, who detected that the PBMCs levels of hsa_circRNA_103636 significantly increased in depressed patients after treatment with antidepressants [68]. Furthermore, using physiotherapy or nerve regulation [i.e., repetitive transcranial magnetic stimulation (rTMS)], Song et al found a significant increase in plasma circDYM levels in depressed patients at the end of treatment and that circDYM can predict the response to rTMS treatment [72]. Recently, Shi et al demonstrated that altered blood circFKBP8 levels can be recovered in depressed patients following effective rTMS treatment and that these were associated with the efficacy of antidepressant treatment [73].…”

Section: Circrnas As Therapeutic Biomarkers For Depressionmentioning

confidence: 99%

See 2 more Smart Citations

Non-coding RNAs in depression: Promising diagnostic and therapeutic biomarkers

et al. 2021

Self Cite

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs), including microRNAs, circular RNAs, and long non-coding RNAs, are important regulators of normal biological processes and their abnormal expression may be involved in the pathogenesis of human diseases including depression. Multiple studies have demonstrated a significantly increased or reduced ncRNAs expression in depressed patients compared with healthy subjects and that antidepressant therapy can alter the aberrant expression of ncRNAs in depressed patients. Although the existing evidence is important, it is also mixed and a comprehensive review to guide an effective clinical translation is lacking. Focused on human research, this review summarizes clinical findings of ncRNAs in depression, including those in brain tissues and peripheral samples. We outlined the characteristics and functions of ncRNAs and highlighted their performance in the diagnosis and treatment of depression. Although their precise roles in depression remain uncertain, ncRNAs have shown potential value as biomarkers for diagnosis and therapy in depressed patients.

show abstract

Section: Circrnas As Diagnostic Biomarkers For Depressionsupporting

confidence: 52%

Section: Circrna Biogenesis and Functionmentioning

confidence: 99%

Section: Circrnas As Therapeutic Biomarkers For Depressionmentioning

confidence: 99%

See 1 more Smart Citation

Non-coding RNAs in depression: Promising diagnostic and therapeutic biomarkers

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…circRNAs have also been shown to be transported in exosomes by RBPs towards multivesicular bodies [34]. Related to our main objective, circDym, a conserved circRNA isoform derived from Dym, has been discovered to function as a microRNA sponge by binding to miR-9 and miR-346 and regulates protein synthesis [35]. Here, we investigated whether circDym speci cally inhibits the synaptic location of mRNA by competitively binding to the RNAtransporting protein.…”

Section: Discussionmentioning

confidence: 99%

circDym prevents chronic neuropathic pain by competitive inhibition of Nlgn2 mRNA transport in neurites

Wang

Liu

Tai

et al. 2021

Preprint

View full text Add to dashboard Cite

Aims: Neuropathic pain (NP) is a chronic syndrome that is refractory to current analgesics through unknown mechanisms. Epigenetic regulation in spinal dorsal horn neurons is reported to contribute to the initiation and maintenance of NP. Circular RNAs (circRNAs) are involved in various biological processes in neurons, but molecular mechanism of how the involvement in NP are lacking. Methods: To study NP, we used a sciatic chronic constriction injury (CCI) model in C57 mice, with the level of mechanical allodynia determined using von Frey monofilaments. The injured ipsilateral spinal dorsal horns in lumbar segments (L3–L5) were collected and total RNA and protein extracted. Transcriptome sequencing, qRT-PCR, western blot analysis, and immunoprecipitation were performed. Bioinformatic analysis was conducted using R packages. The patient cohort was analysed using logistic regression analysis. Results: circDym was identified as one of the NP-related circRNA candidates and qRT-PCR showed that its expression was significantly lower in both the CCI mouse models and in the peripheral blood of patients with NP. Overexpression of circDym significantly attenuated injury induced by NP. Further examination indicated that circDym functions by inhibiting synaptic localization of Nlgn2 mRNA by competitively binding with the RNA-binding protein, Fmrp, resulting in decreased expression of GABAAR, thus leading to the inhibition of chronic pain. Single-cell sequencing results showed that Prodynorphin-positive and Cholecystokinin-positive neurons were likely responsible for this process. Conclusions: We identified circDym, which works through a coupling mechanism, as a novel biomarker and therapeutic target for NP.

show abstract

“…The scales for neuropsychological assessments in three dimensions (affective assessments, social-psychology assessments, and cognitive function assessments) were described in detail in our previous study (53). Briefly, to estimate the affective states of the MDD patients, the HAMD-24, Hamilton Anxiety Scale (HAMA), Beck Scale for Suicide Ideation-Chinese version-Current (BSI-CV-C), Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), and Beck Hopelessness Scale (BHS) were conducted under unified instructions at baseline and day 1, 3, and 5 of treatment.…”

Section: Neuropsychological Assessmentsmentioning

confidence: 99%

Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder

Song

Shi

et al. 2021

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

Background: The evaluation of treatment response to antidepressant therapy commonly depends on neuropsychologic assessments, as there are currently no suitable biomarkers. Previous research has identified a panel of increased proteins in patients with major depressive disorder (MDD), including antithrombin III (ATIII), as potential biomarkers of depression.Methods: A total of 90 MDD patients were recruited. Of these, 74 patients received occipital repetitive transcranial magnetic stimulation (rTMS) as individualized, standard, or sham treatment for 5 days, and underwent the complete procedure, including clinical assessments, blood collection, and protein measurement.Results: After treatment, ATIII was significantly decreased in both the individualized and standard groups (both p < 0.001) relative to the sham group. In the individualized group, reduction in ATIII was associated with improvements in several neuropsychological assessments. Furthermore, ATIII at baseline in the standard group and after individualized rTMS showed good performance for evaluating or predicting the response to five-day treatment (AUC = 0.771, 95% CI, 0.571–0.971; AUC = 0.875, 95% CI, 0.714–1.000, respectively) and remission at follow-up (AUC = 0.736, 95% CI, 0.529–0.943; AUC = 0.828, 95% CI, 0.656–1.000, respectively). Lastly, both baseline ATIII and change in ATIII showed good predictive value for the 24-item Hamilton Depression Rating Scale at follow-up (p = 0.024 and 0.023, respectively).Conclusion: Our study revealed a reduction in ATIII after occipital rTMS in MDD patients and a relationship between change in ATIII and therapeutic response. Taken together, these findings provide evidence for the potential of ATIII as a biomarker for the evaluation and prediction of antidepressive effects.

show abstract

Plasma Circular RNA DYM Related to Major Depressive Disorder and Rapid Antidepressant Effect Treated by Visual Cortical Repetitive Transcranial Magnetic Stimulation

Cited by 28 publications

References 42 publications

Non-coding RNAs in depression: Promising diagnostic and therapeutic biomarkers

Non-coding RNAs in depression: Promising diagnostic and therapeutic biomarkers

circDym prevents chronic neuropathic pain by competitive inhibition of Nlgn2 mRNA transport in neurites

Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder

Contact Info

Product

Resources

About